A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

NCT05139225 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: TTI-622
DRUG: Daratumumab Hyaluronidase-fihj

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]